Eric Rubin started as Vice President of clinical oncology at Merck & Co. in 2008. Since then, he has helped to turn the PD1-targeting pembrolizumab from an almost forgotten antibody into a blockbuster immunotherapy. He also secured a first approval for a tumour-agnostic cancer indication with pembrolizumab earlier this year, and is overseeing more than 300 combination trials to push this drug into more oncology settings. He spoke with Asher Mullard about the future of tumour-agnostic cancer approvals, the complexity of immunotherapy combination trials and recent efforts to modernize cancer trial eligibility criteria.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Eric Rubin. Nat Rev Drug Discov 16, 820–821 (2017). https://doi.org/10.1038/nrd.2017.228
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.228
